Excerpt from the transcript:
Management Quotes "Conference call to discuss the exciting deal that we announced with OptiNose after market closed today. To discuss the details of this exclusive North American license with OptiNose.
Today marks a transformational day for Avanir as we further diversify our CNS product line. After market closed today, we announced a transaction that gives Avanir exclusive North American rights to a novel drug device combination product candidate for the treatment of migraines.
This product aligns extraordinarily well with our current infrastructure and if approved has the ability to contribute significant revenues along side a rapidly growing NUEDEXTA PBA business. This deal marks our second significant business development transaction in 15 months and has a potential to provide a number of value creating milestones to our shareholders in the next 6 months to 18 months. "
Management Quotes "Conference call to discuss the exciting deal that we announced with OptiNose after market closed today. To discuss the details of this exclusive North American license with OptiNose.
Today marks a transformational day for Avanir as we further diversify our CNS product line. After market closed today, we announced a transaction that gives Avanir exclusive North American rights to a novel drug device combination product candidate for the treatment of migraines.
This product aligns extraordinarily well with our current infrastructure and if approved has the ability to contribute significant revenues along side a rapidly growing NUEDEXTA PBA business. This deal marks our second significant business development transaction in 15 months and has a potential to provide a number of value creating milestones to our shareholders in the next 6 months to 18 months. "
Transcript here http://www.earningsimpact.com/Transcript/81846/AVNR/Avanir-Pharmaceuticals%2c-Inc----Business-Update-Call
Tidak ada komentar:
Posting Komentar